Nivolumab/Ipilimumab in Second Line CUP-syndrome

Clinical trial NCT04131621 · UNKNOWN

Trial details

NCT number: NCT04131621
Sponsor: University Hospital Heidelberg
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Cancer of Unknown Primary Site

Start date: 2019-12-12
Primary completion: 2022-12-01
Enrollment: 194

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.